Digital drug

November 2017
New Scientist;11/18/2017, Vol. 236 Issue 3152, p6
The article offers information on the approval of antipsychotic drug, named Abilify MyCite by the U.S. Food and Drug Administration (FDA), which feature an electronic sensor which gets activated upon contact with stomach fluid, sending a message to a patch worn by the patient.


Related Articles

  • News from the FDA.  // Patient Care for the Nurse Practitioner;Jan2007, Vol. 10 Issue 1, p3 

    The article reports on drugs approved by the U.S. Food and Drug Administration. Nonergot dopamine agonist Mirapex has been approved to treat moderate to severe primary restless legs syndrome. Paliperidone Invega derived from risperidone has been approved for the treatment of schizophrenia.

  • Fanapt.  // Pharmaceutical Representative;Jul2009, Vol. 39 Issue 7, p11 

    The article reports on the U.S. Food and Drug Administration's (FDA's) approval of Fanapt (Iloperidone) from Vanda Pharmaceuticals Inc. to treat schizophrenia. It notes that the drug was first developed by Hoechst and licensed to Titan Pharmaceuticals. The company plans to make the drug...

  • New drugs approved in 2009. Sears, Erin; Brooks, Sarah // Baylor University Medical Center Proceedings;Apr2010, Vol. 23 Issue 2, p175 

    The article reviews medications that were approved by the U.S. Food and Drug Administration (FDA) during 2009. Recombinant antithrombin is used for the prevention of perioperative and peripartum thromboembolic events and dosage is based on patient weight and antithrombin activity level....

  • Asenapine. Meltzer, Herbert Y.; Dritselis, Argyris; Yasothan, Uma; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Nov2009, Vol. 8 Issue 11, p843 

    In August 2009, asenapine (Saphris; Schering-Plough) was approved by the US FDA for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults.

  • Iloperidone for the Treatment of Schizophrenia: An Updated Clinical Review. Weiden, Peter J. // Clinical Schizophrenia & Related Psychoses;Apr2012, Vol. 6 Issue 1, p34 

    Iloperidone is a second-generation "atypical" antipsychotic whose primary mechanism of action is within the subclass of combined D2/5HT2A antagonism. Iloperidone was approved by the FDA in May 2009 for the treatment of schizophrenia. This review is a comprehensive synthesis of the history and...

  • Bird Flu Vaccine Looks Promising. Elliott, William T. // Clinical Cardiology Alert;Aug2008 Pharmacology Watch, p1 

    This section offers news briefs on the field of pharmacology in the U.S. as of August 2008. A study found an effective two dose vaccine for the avian flu. The Food and Drug Administration (FDA) is requiring a boxed warning for conventional antipsychotics regarding an increased risk of mortality...

  • FDA Actions. Elliott, William T. // Travel Medicine Advisor;Jul2009 Pharmacology Watch, p2 

    The article focuses on U.S. Food and Drug Authority (FDA) advisories as of July 2009 on certain drugs. FDA has approved AndroGel 1% and Testim 1% which claimed topical testosterone stamina pending the inclusion of a label warning against secondary exposure on children. Likewise, FDA has approved...

  • New atypical antipsychotic approved. Traynor, Kate // American Journal of Health-System Pharmacy;6/15/2009, Vol. 66 Issue 12, p1063 

    The article reports on the approval of the Food and Drug Administration (FDA) to release Vanda Pharmaceuticals Inc.'s Fanapt in the U.S. market. The approval for atypical antipsychotic drug iloperidone aims to minimize the risk of treatment regimen with the dosage of iloperidone to resume...

  • REPORTERSNotebook. Frederick, Jim // Drug Store News;12/10/2007, Vol. 29 Issue 15, p21 

    The article offers pharmaceutical-related news briefs in the U.S. The Food and Drug Administration (FDA) approved revised boxed warnings and other safety-related product labeling changes for erythropoises-stimulating agents, which treat certain types of anemia. FDA also approved a supplemental...

  • NEWS ROUND UP. Spellman, Marguerite // Neuropsychiatry Reviews;Aug2008, Vol. 9 Issue 8, p4 

    The article offers news briefs related to psychiatry in the U.S. A study shows that pregnancy is not associated with an increased risk for the most prevalent mood disorders. British researchers reveal that antipsychotics can reduce violence in patients with schizophrenia. The Food & Drug...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics